Patent classifications
C07C213/06
Continuous Production of Active Pharmaceutical Ingredients
The present invention is directed to a method of producing active pharmaceutical ingredients (APIs). The method includes subjecting a reaction mixture with an API precursor to solvent extraction to produce a reactant stream with the API precursor. The method includes concentrating the API precursor in the reactant stream using at least one membrane. The method includes carrying out a reaction in a membrane reactor. The method includes separating the API precursor from the reaction stream using a separator. The method includes crystallizing the API precursor using a crystallizer to produce APIs.
Continuous Production of Active Pharmaceutical Ingredients
The present invention is directed to a method of producing active pharmaceutical ingredients (APIs). The method includes subjecting a reaction mixture with an API precursor to solvent extraction to produce a reactant stream with the API precursor. The method includes concentrating the API precursor in the reactant stream using at least one membrane. The method includes carrying out a reaction in a membrane reactor. The method includes separating the API precursor from the reaction stream using a separator. The method includes crystallizing the API precursor using a crystallizer to produce APIs.
Continuous Production of Active Pharmaceutical Ingredients
The present invention is directed to a method of producing active pharmaceutical ingredients (APIs). The method includes subjecting a reaction mixture with an API precursor to solvent extraction to produce a reactant stream with the API precursor. The method includes concentrating the API precursor in the reactant stream using at least one membrane. The method includes carrying out a reaction in a membrane reactor. The method includes separating the API precursor from the reaction stream using a separator. The method includes crystallizing the API precursor using a crystallizer to produce APIs.
METHOD FOR PRODUCING HETERO-TYPE MONODISPERSE POLYETHYLENE GLYCOL DERIVATIVE
The present invention provides a method for producing a hetero-type monodisperse polyethylene glycol, which includes a step (A) of carrying out a nucleophilic substitution reaction between a compound of the formula (2) and a compound of the formula (3) so as to satisfy the requirement of the expression (F1) to obtain a compound of the formula (4), a step (B) of carrying out the Michaels addition reaction of a compound of the formula (5) to the compound of the formula (4) at a temperature condition of 10° C. or lower to obtain a compound of the formula (6), a step (C) of detritylating or debenzylating the compound of the formula (6) to obtain a reaction product containing a compound of the formula (7), a step (D) of purifying the compound of formula (7) from the reaction product, a step (E) of reacting the compound of the formula (7) with phthalimide and performing dephthalimidation to obtain a compound of the formula (8), and a step (F) of subjecting the compound of formula (8) to an acid hydrolysis treatment to obtain a compound represented by the formula (1).
METHOD FOR PRODUCING HETERO-TYPE MONODISPERSE POLYETHYLENE GLYCOL DERIVATIVE
The present invention provides a method for producing a hetero-type monodisperse polyethylene glycol, which includes a step (A) of carrying out a nucleophilic substitution reaction between a compound of the formula (2) and a compound of the formula (3) so as to satisfy the requirement of the expression (F1) to obtain a compound of the formula (4), a step (B) of carrying out the Michaels addition reaction of a compound of the formula (5) to the compound of the formula (4) at a temperature condition of 10° C. or lower to obtain a compound of the formula (6), a step (C) of detritylating or debenzylating the compound of the formula (6) to obtain a reaction product containing a compound of the formula (7), a step (D) of purifying the compound of formula (7) from the reaction product, a step (E) of reacting the compound of the formula (7) with phthalimide and performing dephthalimidation to obtain a compound of the formula (8), and a step (F) of subjecting the compound of formula (8) to an acid hydrolysis treatment to obtain a compound represented by the formula (1).
Cationic surfactants comprising an ether link
A cationic surfactant and a method of making the cationic surfactant are described. The method comprises reacting a lipophilic bio-based material having at least one epoxy functional group and a hydrophilic organic compound having at least one cationic functional group and at least one hydroxyl functional group to form a reaction product containing a stable ether linkage connecting the lipophilic bio-based material to the organic compound. At least a portion of the cationic functional groups is neutralized or ion exchanged with an organic acid. Incorporation of the simple organic acid reduces the surfactant's aquatic toxicity and acts as a substrate to encourage co-digestion of the surfactant molecule, making the compound more biodegradable.
Cationic surfactants comprising an ether link
A cationic surfactant and a method of making the cationic surfactant are described. The method comprises reacting a lipophilic bio-based material having at least one epoxy functional group and a hydrophilic organic compound having at least one cationic functional group and at least one hydroxyl functional group to form a reaction product containing a stable ether linkage connecting the lipophilic bio-based material to the organic compound. At least a portion of the cationic functional groups is neutralized or ion exchanged with an organic acid. Incorporation of the simple organic acid reduces the surfactant's aquatic toxicity and acts as a substrate to encourage co-digestion of the surfactant molecule, making the compound more biodegradable.
Cationic surfactants comprising an ether link
A cationic surfactant and a method of making the cationic surfactant are described. The method comprises reacting a lipophilic bio-based material having at least one epoxy functional group and a hydrophilic organic compound having at least one cationic functional group and at least one hydroxyl functional group to form a reaction product containing a stable ether linkage connecting the lipophilic bio-based material to the organic compound. At least a portion of the cationic functional groups is neutralized or ion exchanged with an organic acid. Incorporation of the simple organic acid reduces the surfactant's aquatic toxicity and acts as a substrate to encourage co-digestion of the surfactant molecule, making the compound more biodegradable.
Processes for the Preparation of Zuclomiphene Intermediates
The present invention provides continuous flow processes for the preparation of the compound of Formula (2-A), an intermediate used in the preparation of zuclomiphene or a salt thereof.
##STR00001##
Processes for the Preparation of Zuclomiphene Intermediates
The present invention provides continuous flow processes for the preparation of the compound of Formula (2-A), an intermediate used in the preparation of zuclomiphene or a salt thereof.
##STR00001##